Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Transversus Thoracis Muscle Plane Block for Sternotomy Pain in Cardiac Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04596163
Recruitment Status : Recruiting
First Posted : October 22, 2020
Last Update Posted : March 11, 2022
Sponsor:
Information provided by (Responsible Party):
WONG MAN KIN, Chinese University of Hong Kong

Brief Summary:
Sternotomy pain is usually significant after cardiac surgery. Analgesic options for sternotomy in cardiac surgery are often limited. Poorly controlled acute pain is an important factor to development of chronic postsurgical pain. The transversus thoracis muscle plane (TTP) block is a novel technique that provides analgesia to anterior chest wall. A double-blinded RCT is conducted to assess the efficacy of applying TTP block as an adjunct to analgesia in cardiac surgery.

Condition or disease Intervention/treatment Phase
Pain, Postoperative Surgical Wound Cardiac Event Procedure: Transversus thoracis muscle plane block Not Applicable

Detailed Description:

Chronic postsurgical pain (CPSP) is defined as the persistence of pain at surgical site or referred area, at least 3 months following the surgical procedure. CPSP after median sternotomy is not uncommon after cardiac surgery. The reported incidence ranges from 28% to 56% up to 2 years postoperatively. A number of factors can contribute to the variation in incidence, including the variations in presentation of chronic post-sternotomy pain and under-reporting from patients. Given the nature of cardiac surgery and considerable anxiety of patients at perioperative period, patients would tend to live with the chronic pain and rationalize it as a normal consequence of the surgery. Patients therefore may not report any symptoms, resulting in a delay in diagnosis of chronic post-sternotomy pain.

The mechanisms for development of CPSP after sternotomy are not fully known. The up-regulation, activation and neural sensitization during the acute pain phase are important factors to the development of chronic pain. Causes of pain from sternotomy include neuropathy from anterior intercostal nerves entrapment or injury during surgical dissection and internal mammary artery harvesting, musculoskeletal injury from surgical incision and dissection, sternal fracture or incomplete bone healing, and development of sternal wound infections. Poorly controlled acute pain in the perioperative period can trigger central sensitization, a stepwise modification of spinal pain pathways involving protein synthesis and synaptic strength, which can lead to hyperalgesia and chronic pain. Therefore, good perioperative acute pain control not only provides postoperative pain relief, but also prevents occurrence of chronic pain.

In most centres, opioids such as fentanyl and morphine are used mainly for the management of acute pain after cardiac surgery. However, perioperative opioids are known to be associated with dose-dependent side effects such as nausea and vomiting, pruritis, respiratory depression, postoperative chronic opioid use and increased risk of chronic pain. Multimodal approach such as the use of NSAIDs may not be optimal after cardiac surgery due to the risk of bleeding and renal failure. Regional analgesia has opioid-sparing effect and seems to be a good choice for perioperative anaglesia. Regional techniques such as thoracic epidural and paravertebral blocks have been described but they are not ideal due to the potential complications from systemic heparinization in cardiac surgery. Erector spinae plane (ESP) block was reported to decrease perioperative morphine consumption and early postoperative pain score. However, the transverse process tip is not always easy to visualize on ultrasound, especially in obese patients, resulting in variation in ESP block efficacy.

Transversus thoracis muscle plane (TTP) block covers the anterior branches of intercostal nerves T2 to T6. It has been described in cardiac surgical patients that provides analgesia for sternotomy. TTP block is a superficial block and therefore is relatively safe when compared with thoracic epidural and paravertebral nerve block during heparinization. The investigators hypothesized that pre-emptive TTP block can provide effective perioperative analgesia and prevent the occurrence of CPSP in cardiac surgical patients requiring median sternotomy. A prospective, double-blinded randomized controlled trial was conducted to assess the analgesic efficacy of TTP block in open cardiac surgery.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 86 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Single-centred, double-blinded, randomized, placebo-controlled trial
Masking: Triple (Participant, Care Provider, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Transversus Thoracis Muscle Plane Block for Acute and Chronic Pain Management in Cardiac Surgical Patients Requiring Sternotomy: a Prospective Randomized Controlled Trial
Actual Study Start Date : October 15, 2020
Estimated Primary Completion Date : November 1, 2022
Estimated Study Completion Date : December 31, 2022

Arm Intervention/treatment
Active Comparator: Intervention
Ultrasound guided Regional block using 0.25% levobupivacaine (local anaesthetic agent) 20ml (50mg) on each side of the sternum over 1-2 minutes after general anaesthesia before surgery.
Procedure: Transversus thoracis muscle plane block
After general anaesthesia, transversus thoracis plane (TTP) block, a kind of regional block will be performed near both sides of the sternum under ultrasound guidance using either levobupivacaine or normal saline to both groups of patients. The end point for injection is the fluid spread along the plane just superficial to the transversus thoracis muscle, together with the downward displacement of the pleura.

Placebo Comparator: Control
Ultrasound guided Regional block using 20ml of 0.9% normal saline on each side of the sternum after general anaesthesia before surgery.
Procedure: Transversus thoracis muscle plane block
After general anaesthesia, transversus thoracis plane (TTP) block, a kind of regional block will be performed near both sides of the sternum under ultrasound guidance using either levobupivacaine or normal saline to both groups of patients. The end point for injection is the fluid spread along the plane just superficial to the transversus thoracis muscle, together with the downward displacement of the pleura.




Primary Outcome Measures :
  1. Opioid consumption [ Time Frame: Once at the end of the surgery ]
    The total amount of opioid (mg) used during the surgery


Secondary Outcome Measures :
  1. Percentage blood pressure change [ Time Frame: From 5 minutes before skin incision to 10 minutes after skin incision at 1 minute interval ( a total of 15 time point) ]
    The percentage changes in systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP) between the baseline (before surgery) and within 10 minutes after skin incision for sternotomy

  2. Percentage heart rate change [ Time Frame: From 5 minutes before incision to 10 minutes after skin incision at 1 minute interval (a total of 15 time points) ]
    Heart rate (HR) between the baseline (before surgery) and their peaks within 10 minutes of skin incision for sternotomy.

  3. Morphine consumption [ Time Frame: up to 72 hours postoperatively ]
    The amount of morphine (mg) used after the surgery for pain control

  4. Length of hospital stay [ Time Frame: Immediately after the surgery up to the day of patient discharge ]
    duration of hospital stay (in days)

  5. Intensive Care unit (ICU) stay [ Time Frame: Immediately after the surgery up to the time of ICU discharge ]
    duration of ICU stay (in hours)

  6. Pain score [ Time Frame: At 8, 12, 24, 48 and 72 hours after TTP block and on day 7 after surgery (6 time points). ]
    A visual analogue scale of 0-10 (0=no pain, 10=worst pain) will be used to grade the pain score. Patients will be asked to rate the intensity of postoperative pain at rest and on three maximal coughs.

  7. Peak expiratory flow rate [ Time Frame: Once as baseline on the day before operation and at 6 time points after surgery (ie. at 8, 12, 24, 48, 72 hours after block and on day 7 after surgery). ]
    Measured with a spirometer at baseline on the day before operation and postoperatively at the time of assessing pain score. The higher the result means the better the lung function of the patient.

  8. Forced expiratory volume in 1 second [ Time Frame: Once as baseline on the day before operation and at 6 time points after surgery (ie. at 8, 12, 24, 48, 72 hours after block and on day 7 after surgery). ]
    Measured with a spirometer at baseline on the day before operation and postoperatively at the time of assessing pain score. The higher the result means the better the lung function of the patient.

  9. Brief Pain Interference Scale [ Time Frame: at 3-month and 6-month after surgery ]
    It will be used to evaluate the extent of pain interfering with various components of functioning, including physical functioning, emotional functioning and sleep within the last 24 hours at 3 and 6 months after surgery (a score of 0-10; 0=no interference at all, 10= the worst interference due to pain).

  10. Pain Catastrophizing Scale [ Time Frame: at 3-month and 6-month after surgery ]
    Pain Catastrophizing Scale (HK-PCS) will be used to assess patients' negative cognitive-affective responses to pain within the last 24 hours at 3 and 6 months after surgery. Score 0-100 (0=no pain related anxiety; 100=most severe pain related anxiety)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Elective CABG, aortic valve repair/replacement, mitral valve repair/replacement, or combined CABG/valve procedure

Exclusion Criteria:

  • emergency surgery
  • redo surgery
  • history of thoracotomy or mastectomy
  • history of chronic pain or regular analgesic use (except paracetamol and NSAID)
  • history of psychiatric illnesses or illicit drug use
  • renal failure with eGFR <30ml/min or on renal replacement therapy
  • mortality or require re-sternotomy within 24h after operation
  • intraoperative use of remifentanil
  • unable to provide informed consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04596163


Contacts
Layout table for location contacts
Contact: Henry Man Kin Wong, MBChB 55699559 mkw118@gmail.com

Locations
Layout table for location information
Hong Kong
Prince of Wales Hospital Recruiting
Hong Kong, Hong Kong
Contact: Henry Man Kin Wong, MBChB    55699559    mkw118@gmail.com   
Sponsors and Collaborators
Chinese University of Hong Kong
Investigators
Layout table for investigator information
Principal Investigator: Henry Man Kin Wong, MBChB Chinese University of Hong Kong
Layout table for additonal information
Responsible Party: WONG MAN KIN, Honorary Clinical Assistant Professor, Chinese University of Hong Kong
ClinicalTrials.gov Identifier: NCT04596163    
Other Study ID Numbers: 2020.371-T
First Posted: October 22, 2020    Key Record Dates
Last Update Posted: March 11, 2022
Last Verified: March 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by WONG MAN KIN, Chinese University of Hong Kong:
Regional anaesthesia
Cardiac surgery
Additional relevant MeSH terms:
Layout table for MeSH terms
Pain, Postoperative
Surgical Wound
Postoperative Complications
Pathologic Processes
Pain
Neurologic Manifestations
Wounds and Injuries